BioAlliance Pharma' Sitavig shows marked efficacy in treating cold sores

French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has presented positive results of the pharmacokinetic and pharmacodynamic study on Sitavig (acyclovir Lauriad) in the treatment of labial herpes (cold sores) at the 10th spring symposium of the European Academy of Dermatology and Venereology in Cracow, Poland.

“This study has shown that Sitavig, a mucoadhesive buccal tablet, delivers early, very high and prolonged concentrations of acyclovir at the replication site of the herpes virus. Salivary and labial acyclovir concentrations are markedly over those obtained with the other antiviral drugs,” commented Pierre Attali, chief operating officer of BioAlliance Pharma in charge of strategy and medical affairs, adding: “This pharmacokinetic profile supported the rationale for a single administration of Sitavig to treat cold sores as soon as the first signs or symptoms occur.”

Together with the marked efficacy on healing time and on pain as well as an excellent safety profile demonstrated in the international Phase III trial (LIP study), these results enabled the company to obtain the registration of Sitavig in eight first European countries and in the USA (The Pharma Letters April 16, 2013 and December 20, 2012). In addition to its efficacy, Sitavig offers a unique discreet and simple formulation with a single application, representing major advantages for patients suffering from recurrent cold sores, said BioAlliance.